Globus Medical Inc (NYSE:GMED) President Anthony L. Williams sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $38.30, for a total transaction of $574,500.00. Following the sale, the president now owns 15,000 shares of the company’s stock, valued at approximately $574,500. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Globus Medical Inc (NYSE:GMED) traded up $0.56 during trading on Thursday, reaching $38.99. 497,100 shares of the company traded hands, compared to its average volume of 687,066. Globus Medical Inc has a 12-month low of $23.44 and a 12-month high of $41.70. The firm has a market cap of $3,703.73, a P/E ratio of 30.74, a PEG ratio of 2.92 and a beta of 0.58.

Globus Medical (NYSE:GMED) last posted its earnings results on Wednesday, November 8th. The medical device company reported $0.30 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.30. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. The firm had revenue of $151.74 million during the quarter, compared to the consensus estimate of $150.73 million. During the same quarter last year, the firm earned $0.29 EPS. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. analysts predict that Globus Medical Inc will post 1.27 EPS for the current year.

A number of brokerages have recently issued reports on GMED. ValuEngine downgraded shares of Globus Medical from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Wells Fargo & Company upgraded shares of Globus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target for the company in a report on Monday, December 4th. Gabelli restated a “buy” rating on shares of Globus Medical in a report on Tuesday, November 14th. BTIG Research set a $42.00 price target on shares of Globus Medical and gave the stock a “buy” rating in a report on Monday, November 20th. Finally, Zacks Investment Research upgraded shares of Globus Medical from a “sell” rating to a “hold” rating in a report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. Globus Medical has a consensus rating of “Hold” and a consensus target price of $36.83.

A number of institutional investors have recently bought and sold shares of GMED. PNC Financial Services Group Inc. increased its holdings in Globus Medical by 1.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,036 shares of the medical device company’s stock valued at $100,000 after purchasing an additional 35 shares during the last quarter. Sei Investments Co. grew its stake in shares of Globus Medical by 18.9% in the second quarter. Sei Investments Co. now owns 3,165 shares of the medical device company’s stock worth $105,000 after acquiring an additional 503 shares in the last quarter. Advisor Group Inc. grew its stake in shares of Globus Medical by 2.0% in the second quarter. Advisor Group Inc. now owns 3,434 shares of the medical device company’s stock worth $114,000 after acquiring an additional 68 shares in the last quarter. Turner Investments LLC acquired a new position in shares of Globus Medical in the second quarter worth $166,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Globus Medical in the third quarter worth $177,000. Hedge funds and other institutional investors own 72.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/14/globus-medical-inc-gmed-president-sells-574500-00-in-stock.html.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Receive News & Stock Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related stocks with our FREE daily email newsletter.